ASX:SNT

3 stories mentioning ASX:SNT

Every FINWIRES story that references ASX:SNT, newest first.

Syntara Completes Share Purchase Plan

Syntara (ASX:SNT) completed its share purchase plan, with applications received totalling around AU$840,000, and a total of 31.2 million new fully paid ordinary shares will be issued, according to a Wednesday Australian bourse filing.Shares were offered under the plan at an issue price of AU$0.027 apiece.It will use the proceeds alongside the AU$8 million raised via a placement to fund five key clinical trial readouts within the year, to progress current licensing discussions across the pipeline, and to prepare for a phase 2b study.

ASX:SNT

Asia48d ago

Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment

Syntara (ASX:SNT) received positive feedback from the US Food and Drug Administration following a type C meeting, supporting the design of its planned phase 2b clinical trial of amsulostat for the treatment of myelofibrosis, according to a Tuesday filing with the Australian bourse.The primary endpoint of the phase 2b study will be the achievement of a 50% reduction in the total symptom score following nine months of treatment, with about 100 patients expected to be enrolled, per the filing.The positive feedback from the US FDA allows for amsulostat's progression into late-stage clinical development and paves the way for further engagement with prospective commercial partners, the company said.Myelofibrosis is a type of bone marrow cancer where the accumulation of scar tissue leads to a loss of red and white blood cells and platelets.

ASX:SNT

Asia59d ago

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.

ASX:SNT